Author(s): Weiner LM, Murray JC, Shuptrine CW
Abstract Share this page
Abstract By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated efficacy as cancer therapeutics. Recent successful antibody-based strategies have focused on enhancing antitumor immune responses by targeting immune cells, irrespective of tumor antigens. We discuss these innovative strategies and propose how they will impact the future of antibody-based cancer therapy. Copyright © 2012 Elsevier Inc. All rights reserved.
This article was published in Cell
and referenced in Journal of Integrative Oncology